Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN MCL-321 in previously treated BTK inhibitor-naive mantle cell lymphoma
NL-OMON54133Phase 3Recruiting
- Sponsor
- Loxo Oncology
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib, ibrutinib, acalabrutinib and zanubrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
pirtobrutinibibrutinibacalabrutinibzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON54133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54133.